Follow The Filings

Avidity Partners Management LP David Witzke

Dallas, TX 21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $624M
  • 45 holdings
  • 2026 Q2
  • +41.2% QoQ
  • Top 5 70.9%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 45 holdings

Top 5 70.9%, top 10 81.9%

  1. DNTH, Dianthus Therapeutics 32.8%
  2. CGON, CG Oncology 15.9%
  3. ORKA, Oruka Therapeutics 11.6%
  4. JBIO, Jade Biosciences 6.1%
  5. ELVN, Enliven Therapeutics 4.5%
  6. CATX, Perspective Therapeutics 3.4%
  7. AKTS, Aktis Oncology 2.5%
  8. PVLA 1.7%
  9. MOBI, Mobia Medical 1.7%
  10. RGEN, Repligen 1.7%
  11. Immunic 1.6%
  12. Senseonics 1.5%
  13. Other 15.0%

AUM over time

2026 Q2 $624M +41.2% QoQ
2021 Q3: $4.5B 2021 Q3: $4.5B
Q3 2021
2021 Q4: $4.7B, +4.5% QoQ 2021 Q4: $4.7B, +4.5% QoQ
Q4
2022 Q1: $4.8B, +1.9% QoQ 2022 Q1: $4.8B, +1.9% QoQ
Q1 2022
2022 Q2: $4.4B, −9.3% QoQ 2022 Q2: $4.4B, −9.3% QoQ
Q2
2022 Q3: $4.9B, +12.9% QoQ 2022 Q3: $4.9B, +12.9% QoQ
Q3
2022 Q4: $4.6B, −6.2% QoQ 2022 Q4: $4.6B, −6.2% QoQ
Q4
2023 Q1: $3B, −34.7% QoQ 2023 Q1: $3B, −34.7% QoQ
Q1 2023
2023 Q2: $2.9B, −5.0% QoQ 2023 Q2: $2.9B, −5.0% QoQ
Q2
2023 Q3: $2.5B, −13.3% QoQ 2023 Q3: $2.5B, −13.3% QoQ
Q3
2023 Q4: $2.7B, +10.5% QoQ 2023 Q4: $2.7B, +10.5% QoQ
Q4
2024 Q1: $3.1B, +13.0% QoQ 2024 Q1: $3.1B, +13.0% QoQ
Q1 2024
2024 Q2: $2.4B, −24.1% QoQ 2024 Q2: $2.4B, −24.1% QoQ
Q2
2024 Q3: $2B, −16.7% QoQ 2024 Q3: $2B, −16.7% QoQ
Q3
2024 Q4: $1B, −48.1% QoQ 2024 Q4: $1B, −48.1% QoQ
Q4
2025 Q1: $525M, −48.4% QoQ 2025 Q1: $525M, −48.4% QoQ
Q1 2025
2025 Q2: $502M, −4.4% QoQ 2025 Q2: $502M, −4.4% QoQ
Q2
2025 Q3: $439M, −12.5% QoQ 2025 Q3: $439M, −12.5% QoQ
Q3
2025 Q4: $347M, −21.0% QoQ 2025 Q4: $347M, −21.0% QoQ
Q4
2026 Q1: $442M, +27.4% QoQ 2026 Q1: $442M, +27.4% QoQ
Q1 2026
2026 Q2: $624M, +41.2% QoQ 2026 Q2: $624M, +41.2% QoQ
Q2

Book

2022 Q2 2022 Q1, filed 15 Aug, long equity only

Download CSV Download Excel All activity
AZNN 5.31% Reduce −5.4% 3,499,000 $66.07 $231M −201,000 −$14M
VRTX, Vertex Pharmaceuticals 5.13%, was 2.96% Add +45.3% 793,000 $281.79 $223M +247,400 +$81M
ARGX, Argenx 4.98%, was 1.16% Add +225.3% 572,500 $378.88 $217M +396,500 +$161M
ELV, Elevance Health 4.89%, was 4.09% Add +10.4% 441,000 $482.58 $213M +41,600 +$17M
AVTR, Avantor 4.75%, was 3.99% Add +17.4% 6,652,700 $31.10 $207M +984,400 +$15M
LLY, Eli Lilly 4.54% New 610,000 $324.23 $198M +610,000 +$198M
HUM, Humana 4.43%, was 1.80% Add +107.3% 412,300 $468.07 $193M +213,400 +$106M
UTHR, United Therapeutics 3.93%, was 2.69% Add +0.9% 725,600 $235.64 $171M +6,654 +$42M
JNJ, Johnson & Johnson 3.67%, was 1.31% Add +154.3% 900,200 $177.51 $160M +546,200 +$97M
Horizon Therapeutics Pub 3.40%, was 2.48% Add +64.1% 1,856,900 $79.76 $148M +725,500 +$29M
NBIX, Neurocrine Biosciences 3.28%, was 2.26% Add +26.5% 1,467,600 $97.48 $143M +307,600 +$34M
ARVN, Arvinas 3.24% Add +15.1% 3,355,623 $42.09 $141M +440,323 −$55M
XBI, SPDR Ser Trust 3.20%, was 0.82% Add +326.1% 1,875,000 $74.27 $139M +1,435,000 +$100M
MCK, McKesson 2.91%, was 1.21% Add +105.2% 388,800 $326.21 $127M +199,300 +$69M
UNH, UnitedHealth Group 2.86% Reduce −6.7% 242,200 $513.63 $124M −17,400 −$8M
ABBV, AbbVie 2.65%, was 4.95% Reduce −48.5% 755,000 $153.16 $116M −711,100 −$122M
SNDX, Syndax Pharmaceuticals 2.41%, was 1.75% Add +13.0% 5,450,000 $19.24 $105M +626,600 +$21M
Catalent 2.35%, was 1.81% Add +22.1% 955,000 $107.29 $102M +173,000 +$16M
ZNTL, Zentalis Pharmaceuticals 2.31% Add +12.9% 3,585,881 $28.10 $101M +408,882 −$46M
Seagen 2.23%, was 0.30% Add +450.0% 550,000 $176.94 $97M +450,000 +$83M
BSX, Boston Scientific 2.16%, was 1.10% Add +111.1% 2,525,000 $37.27 $94M +1,328,900 +$41M
BIIB, Biogen 2.06%, was 1.60% Add +20.7% 440,566 $203.94 $90M +75,566 +$13M
RARE 2.03%, was 1.31% Add +70.3% 1,479,500 $59.66 $88M +610,500 +$25M
ACHC 1.61% New 1,035,000 $67.63 $70M +1,035,000 +$70M
INTC, Intellia Therapeutics 1.34%, was 0.59% Add +188.5% 1,125,194 $51.76 $58M +735,119 +$30M
Legend Biotech 1.26% Reduce −8.7% 1,000,000 $55.00 $55M −95,000 +$15M
ARWR, Arrowhead Pharmaceuticals 1.16%, was 0.91% Add +50.7% 1,438,999 $35.21 $51M +483,999 +$6.7M
Immunocore 1.16% Reduce −1.0% 1,350,000 $37.31 $50M −13,800 +$9.6M
NTRA, Natera 1.11%, was 1.10% Add +5.3% 1,369,100 $35.44 $49M +69,100 −$4.4M
Intra-Cellular Therapies 1.02% New 775,504 $57.08 $44M +775,504 +$44M
IDYA, Ideaya Biosciences 0.94%, was 0.63% Add +10.5% 2,972,947 $13.80 $41M +282,947 +$11M
Bellus Health 0.90%, was 0.53% Add +15.7% 4,265,000 $9.24 $39M +580,000 +$14M
ALT, Altimmune 0.80%, was 0.36% Add +4.0% 2,981,000 $11.70 $35M +116,000 +$17M
Kezar Life Sciences 0.77% Add +15.1% 4,050,000 $8.27 $33M +532,000 −$25M
RNA, Avidity Biosciences 0.69% Add +1.7% 2,080,200 $14.53 $30M +35,200 −$7.5M
Karuna Therapeutics 0.59% New 204,570 $126.51 $26M +204,570 +$26M
RVMD, Revolution Medicines 0.59% New 1,325,000 $19.49 $26M +1,325,000 +$26M
ARKG, Ark ETF Trust 0.54% New 750,000 $31.49 $24M +750,000 +$24M
VIR, Vir Biotechnology 0.44% Reduce −2.8% 758,211 $25.47 $19M −21,789 −$750K
Nkarta 0.40% New 1,414,082 $12.32 $17M +1,414,082 +$17M
PHAT, Phathom Pharmaceuticals 0.37%, was 0.55% Reduce −1.3% 1,919,800 $8.44 $16M −26,200 −$10M
CRBU, Caribou Biosciences 0.37% Add +4.6% 2,950,000 $5.43 $16M +130,933 −$9.9M
Holding 0.36% New 1,200,000 $13.15 $16M +1,200,000 +$16M
NUVB, Nuvation Bio 0.36%, was 0.53% Reduce 0.0% 4,855,000 $3.24 $16M −6 −$9.8M
IOVA, Iovance Biotherapeutics 0.35%, was 2.10% Reduce −77.0% 1,392,300 $11.04 $15M −4,650,919 −$85M
XENE, Xenon Pharmaceuticals 0.31% New 450,000 $30.42 $14M +450,000 +$14M
SIBN, Si-Bone 0.30% Hold 1,000,000 $13.20 $13M — —
Seaspine 0.26% Hold 2,010,000 $5.65 $11M — —
ATEC, Alphatec 0.26%, was 0.66% Reduce −37.3% 1,715,000 $6.54 $11M −1,020,600 −$20M
APLS, Apellis Pharmaceuticals 0.22% Add +2.4% 215,000 $45.22 $9.7M +5,000 −$948K

Showing top 50 of 80 by value

Exits / last held

Gone since 2022 Q1, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
MRK, Merck 4.05% Exit 0 $82.05 $194M −2,370,000 −$194M
BAX, Baxter International 3.09% Exit 0 $77.54 $149M −1,915,500 −$149M
BHVN, Biohaven 3.04% Exit 0 $118.57 $146M −1,231,000 −$146M
Mirati Therapeutics 2.38% Exit 0 $82.22 $115M −1,393,000 −$115M
ISRG, Intuitive Surgical 2.04% Exit 0 $301.68 $98M −325,000 −$98M
Adicet Bio 1.30% Exit 0 $19.97 $62M −3,120,000 −$62M
EW, Edwards Lifesciences 1.08% Exit 0 $117.72 $52M −440,000 −$52M
BHC, Bausch Health Companies 0.81% Exit 0 $22.85 $39M −1,694,700 −$39M
INSM, Insmed 0.66% Exit 0 $23.50 $32M −1,354,539 −$32M
Chemocentryx 0.61% Exit 0 $25.07 $29M −1,175,000 −$29M
AXSM, Axsome Therapeutics 0.61% Exit 0 $41.39 $29M −711,000 −$29M
RCUS, Arcus Biosciences 0.60% Exit 0 $31.56 $29M −912,000 −$29M
PEN, Penumbra 0.48% Exit 0 $222.13 $23M −104,000 −$23M
Viridian Therapeutics 0.40% Exit 0 $18.49 $19M −1,040,000 −$19M
Blueprint Medicines 0.39% Exit 0 $63.88 $19M −291,184 −$19M
LKFT, Galapagos 0.28% Exit 0 $62.02 $13M −215,000 −$13M
Holding 0.10% Exit 0 $9.87 $4.9M −500,000 −$4.9M
Helix Acquisition 0.09% Exit 0 $11.10 $4.4M −400,000 −$4.4M
Gritstone Bio 0.05% Exit 0 $4.12 $2.3M −560,000 −$2.3M

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2022 Q1. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 45 $624M +41.2% 13F-HR 8/14/2026 000179182726000005
2026 Q1 45 $494M — new holds 5/28/2026 000179182726000004
2026 Q1 46 $442M +27.4% 13F-HR 5/13/2026 000179182726000003
2025 Q4 39 $347M −21.0% 13F-HR 2/13/2026 000179182726000002
2025 Q3 43 $439M −12.5% 13F-HR 11/14/2025 000179182725000008
2025 Q2 56 $502M −4.4% 13F-HR 8/14/2025 000179182725000007
2025 Q1 67 $525M −48.4% 13F-HR 5/15/2025 000179182725000005
2024 Q4 63 $1B −48.1% 13F-HR 2/14/2025 000179182725000002
2024 Q3 81 $2B −16.7% 13F-HR 11/14/2024 000179182724000011
2024 Q2 85 $2.4B −24.1% 13F-HR 8/14/2024 000179182724000007
2024 Q1 90 $3.1B +13.0% 13F-HR 5/15/2024 000179182724000004
2023 Q4 74 $2.7B +10.5% 13F-HR 2/14/2024 000179182724000002
2023 Q3 83 $2.5B −13.3% 13F-HR 11/14/2023 000179182723000006
2023 Q2 93 $2.9B −5.0% 13F-HR 8/14/2023 000179182723000004
2023 Q1 83 $3B −34.7% 13F-HR 5/15/2023 000179182723000003
2022 Q4 85 $4.6B −6.2% 13F-HR 2/14/2023 000179182723000002
2022 Q3 97 $4.9B +12.9% 13F-HR 11/14/2022 000179182722000008
2022 Q2 82 $4.4B −9.3% 13F-HR 8/15/2022 000179182722000006
2022 Q1 92 $4.8B +1.9% 13F-HR 5/16/2022 000179182722000004
2021 Q4 97 $4.7B +4.5% 13F-HR 2/14/2022 000179182722000002
2021 Q3 105 $4.5B — 13F-HR 11/15/2021 000179182721000006

About

Avidity Partners Management LP

21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Avidity Partners Management LP
Notable person
David Witzke
Location
Dallas, TX
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf